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Purpose/objective(s): To report outcomes and toxicity for patients with oligometastatic
(≤5 lesions) prostate cancer (PCa) treated with stereotactic body radiation therapy (SBRT).
Materials/methods: Seventeen men with 21 PCa lesions were treated with SBRT
between February 2009 and November 2011. All patients had a detectable prostate-speciﬁc
antigen (PSA) at the time of SBRT, and 11 patients (65%) had hormone-refractory (HR)
disease.Treatment sites included bone (n = 19), lymph nodes (n = 1), and liver (n = 1). For
patients with bone lesions, the median dose was 20 Gy (range, 8–24 Gy) in a single fraction
(range, 1–3). All but two patients received some form of anti-androgen therapy after
completing SBRT. Results: Local control (LC) was 100%, and the PSA nadir was
undetectable in nine patients (53%).The ﬁrst post-SBRT PSAwas lower than pre-treatment
levels in 15 patients (88%), and continued to decline or remain undetectable in 12 patients
(71%) at a median follow-up of 6 months (range, 2–24 months). Median PSA measure-
ments before SBRT and at last follow-up were 2.1 ng/dl (range, 0.13–36.4) and 0.17 ng/dl
(range, <0.1–140), respectively. Six (55%) of the 11 patients with HR PCa achieved either
undetectable or declining PSA at amedian follow-up of 4.8months (range, 2.2–6.0months).
Reported toxicities included one case each of grade 2 dyspnea and back pain, there were
no cases of grade ≥3 toxicity following treatment. Conclusion: We report excellent LC
with SBRT in oligometastatic PCa. More importantly, over half the patients achieved an
undetectable PSA after SBRT. Further follow-up is necessary to assess the long-term impact
of SBRT on LC, toxicity, PSA response, and clinical outcomes.
Keywords: stereotactic body radiation therapy, stereotactic radiosurgery, prostatemetastases, intensity-modulated
radiation therapy, prostate-specific antigen, bone metastases
INTRODUCTION
Prostate cancer (PCa) is the most common non-skin cancer in
men in the United States, with 1 in 36 men dying from the dis-
ease (American Cancer Society, 2010). Androgen deprivation is
often the treatment of choice for patients with a new diagnosis
of metastatic or locally advanced PCa. In the metastatic setting,
androgen deprivation is associatedwith a response rate of 80–90%,
and overall survival estimates range from 24 to 36 months (Heller-
stedt andPienta, 2002). Patients with hormone-refractory prostate
cancer (HRPC) often have distant metastatic disease, and bony
metastases may result in signiﬁcant morbidity and a decline in
quality-of-life (Weinfurt et al., 2002). Current palliative treatment
options for patients with hormone-refractory (HR) metastatic
PCa include external beam radiation therapy (EBRT), and/or
systemic radiopharmaceuticals, chemotherapy, bisphosphonates,
surgery, and analgesics.
Stereotactic body radiation therapy (SBRT) uses similar tech-
niques as central nervous system (CNS)-based stereotactic radio-
surgery but treats tumors outside of the CNS using a coordinate
system,which allows for limitedbut highly precise treatmentﬁelds.
It offers some distinct advantages over conventional EBRT for
patients with oligometastatic cancer, including a shorter treatment
course, possibly better disease control (Yamada et al., 2008), and
the ability to treat in the setting of re-irradiation while sparing
more normal anatomy (Sahgal et al., 2009). In addition, SBRT
offers a more effective radiobiologic dose (Fowler et al., 2004).
Patients with ﬁve or fewer metastatic lesions on diagnostic
imaging studies are of a particular interest as their disease bur-
den may be small enough that a change in a tumor marker, such
as prostate-speciﬁc antigen (PSA) in PCa, may be noted and fol-
lowed serially to monitor tumor response to treatment. In the
current study, we report our center’s experience from a prospec-
tive database of patients treated with SBRT for oligometastatic
PCa (≤5 PCa lesions on diagnostic imaging), many of whom had
previously been diagnosed with HR disease.
MATERIALS AND METHODS
This study included17patientswith 21oligometastatic PCa lesions
treated with SBRT at our institution between February 2009 and
November 2011. Data for these patients was prospectively col-
lected and analyzed for this review. This study was approved by the
Institutional Review Board (IRB) at our institution and informed
consentwas obtained fromall patients. Eligibility included biopsy-
proven PCa, Karnofsky performance status (KPS) >40 with life
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expectancy >3 months, and conﬁrmation of metastases using
(11)C-choline positron emission tomography/computed tomog-
raphy (11CPET/CT; n = 7), magnetic resonance imaging (MRI;
n = 6), biopsy (n = 1), CT (n = 1), or both 11CPET/CT and
MRI (n = 2). Eleven patients had HRPC, which was deﬁned as an
increase in the serum PSA level over the baseline level ≥2 consec-
utive samples obtained ≥7 days apart despite receiving androgen
deprivation therapy (ADT). In patients diagnosed with HRPC,
a change in ADT sequencing from continuous to intermittent
often occurred; however, ADT was not routinely discontinued or
changed.
SBRT TECHNIQUE
Techniques for SBRT immobilization and treatment planning
from our center have been described previously and are sum-
marized as follows (Macdonald et al., 2009). Each patient was
immobilized using the Body-Fix whole-body or thoracic-T double
vacuum immobilization system (Medical Intelligence, Schwab-
münchen, Germany). Axial CT images were obtained on a Light
Speed RT 16-slice CT simulator (GE HealthCare, Milwaukee,
WI, USA). Image acquisition was set at 1.25-mm slice thickness.
Four-dimensional CT images were obtained for patients treated
to non-bony sites using the Varian Real-time Position Manage-
ment (RPM) system (Varian, Palo Alto, CA, USA). Respiratory
monitoring was conducted with an infrared reﬂector placed on
the patient’s chest. Normal tissue and tumor segmentation was
performed on the Advantage SimMD software (Advantage Work-
station, GE Healthcare, Milwaukee, WI, USA). When available,
diagnostic imaging (MRI, PET, contrasted CT scans) was fused to
planning imaging to aid in gross tumor volume (GTV)delineation.
For non-bony lesions, an internal target volume (ITV) was created
from theGTV to account for tumormotion associatedwith patient
respiration. The clinical target volume (CTV) was considered to
be identical to the GTV for bony lesions or the ITV for non-bony
lesions. The planning target volume (PTV) typically consisted of a
uniform 5 mm expansion of the CTV. A dose–volume histogram
was generated for organs in the vicinity of the PTV.
Both intensity-modulated radiation therapy (IMRT) and 3D-
conformal SBRT treatment plans were designed using the Eclipse
(Varian) treatment planning software. Often when IMRT was
used, a heterogeneous dose distribution was achieved by pre-
scribing a higher dose to the GTV relative to the PTV, creating
a cloud of increased dose around gross disease while meeting
radiation dose constraints on normal tissues adjacent or near the
target volumes. Details regarding internally validated normal tis-
sue organ-at-risk (OAR) constraints employed at our institution
have been previously published (Barney et al., 2011).
Daily image guidance was performed using the ExacTRAC
6D X-ray system (Brainlab, Feldkirchen, Germany) with the 6D
robotic couch for bony lesions or cone-beam CT (CBCT) for
non-bony lesions. With ExacTRAC, initial corrections were auto-
matically applied based on initial set-up imaging. Veriﬁcation
imaging using both tube-detector pairs was repeated to conﬁrm
positioning within 1 mm and 1◦. Prior to delivering each treat-
ment ﬁeld, a “snap”veriﬁcation image using a single tube-detector
pair was acquired to verify positioning, and full imaging veriﬁca-
tion and shifting were repeated if the snap veriﬁcation image was
off by>2 mm. With CBCT, an initial CBCT scan was acquired,
a match was manually performed, and the shift was applied.
Any shift >0.3 cm required a second CBCT acquisition to verify
position.
Stereotactic body radiation therapy dose was chosen based on
previously published studies for the treatment of bony and soft
tissue oligometastasis (Salama et al., 2008; Yamada et al., 2008),
proximity of critical structures, and whether the area in question
had been previously irradiated. The normal tissue constraints used
for these treatments have been published previously (Barney et al.,
2011; Ahmed et al., 2012) and are similar to those employed at
other institutions with a high-volume SBRT practice.
EVALUATION OF RESPONSE
Local control (LC)was determinedby apatient’smost recent imag-
ing and was deﬁned as a lack of tumor progression within the
PTV. Freedom from distant progression (FFDP) was deﬁned as no
development of new metastases and/or progression of untreated
metastases. PSA testing was performed both immediately prior
to SBRT and approximately 2 months after completion of SBRT.
Follow-up thereafter included history and physical examination,
serum PSA testing, and imaging studies as indicated every 2–
3 months. Toxicity was evaluated and graded according to the
National Cancer Institute (NCI) Common Terminology Crite-
ria for Adverse Events (CTCAE) v3.0 (National Cancer Institute,
2006). Late effects were designated as events occurring 3 months
following treatment.
STATISTICS
The Kaplan–Meier (KM) method was used to estimate rates of
LC, FFDP, and prostate cancer-speciﬁc survival (CSS). Survival
and disease control were calculated from the end of SBRT. The
Wilcoxon signed-rank test was used to test differences in pre-SBRT
PSA values against 2-month post-SBRT values and at the time
of most recent follow-up. In all cases, a p-value of <0.05 was
considered signiﬁcant. All statistical analysis was performed with
JMP 8.0 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Table 1 summarizes patient and disease characteristics at the time
of SBRT. The median patient age for the cohort was 65.0 years
(range, 50.6–79.7). Initial Gleason scores (GS) were as follows: GS
6 (n = 1), GS 7 (n = 9), GS 8 (n = 3), and GS 9 (n = 4). All patients
had previously undergone deﬁnitive therapy prior to developing
distant metastasis (DM). The median time from initial diagnosis
of PCa to the development of DM was 50.4 months (range, 1.0–
139.2 months). Eleven patients (65%) had HRPC at the time of
SBRT, and in these men, the median duration of hormone therapy
prior to developing HR disease was 14.0 months (range, 4.0–108.0
months). Likewise, the median duration from developing HR dis-
ease to treatment with SBRT was 13.0 months (range, 1.0–80.4
months). Sites treated with SBRT included bone (n = 19), lymph
nodes (n= 1), and liver (n= 1). For patients with bone lesions, the
median dosewas 20Gy (range, 8–24Gy) in a single fraction (range,
1–3). Figure 1 shows an example of target and normal tissue con-
tours with associated isodose curves for a bony lesion located
in the anterior portion of the T3 vertebral body. The patient
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Table 1 | Patient and disease characteristics at the time of SBRT.
Characteristic All patients,
n = 17
HRPC,
n = 11
Non-HRPC,
n = 6
Lesions treated (n) 21 14 7
Age (year)
Median 65.0 66.9 60.3
Range 50.6–79.7 52.9–79.7 50.6–74.0
Initial Gleason score (n)
6 1 1 0
7 9 6 3
8 3 1 2
9 4 3 1
Primary therapy at diagnosis (n)
Prostatectomy 15 9 6
EBRT 2 2 0
Time from diagnosis to DM (month)
Median 50.4 63.0 28.0
Range 1.0–139.2 1.0–139.2 1.0–66.0
Time to development of HRPC (month)
Median – 14.0 –
Range – 4.0–108.0 –
Time from HRPC to SBRT (month)
Median – 13.0 –
Range – 1.0–80.4 –
Site treated with SBRT (n)
Bone 19 12 7
Liver 1 1 –
Retroperitoneal
lymph nodes
1 1 –
HRPC, hormone-refractory prostate cancer; EBRT, external beam radiation
therapy; DM, distant metastasis; SBRT, stereotactic body radiation therapy.
with metastases to retroperitoneal lymph nodes was treated with
50 Gy in ﬁve fractions, and the patient with metastases to the liver
received 60 Gy in three fractions. Fifteen patients (88%) received
some form of androgen suppression after completion of SBRT.
Table 2 outlines each individual patient’s treatment course and
clinical outcome. Sixteen of the 21 lesions (76%) were evaluable
for LC, and at a median follow-up of 6 months (range, 2–24
months), no patient had experienced a local recurrence. Six- and
twelve-month estimates of CSS were 100% (Figure 2), though two
patients had died from distant cancer progression at the date of
last follow-up. Six- and twelve-month estimates of FFDP were 74
and 40%, respectively (Figure 3).
Prostate-speciﬁc antigen data was available for all 17 patients,
and 9 (52.9%) patients reached undetectable PSA at a median
of 3 months (range, 1–8 months) following SBRT. Of these
nine patients, three (33%) had HRPC. With the exception of
two patients (12%) who developed distant progression, all other
patients (n = 15; 88%) experienced a decrease in PSA on the ﬁrst
FIGURE 1 | Contours and isodose curves for a patient treated to 18 Gy
in a single fraction to an right anteriorT3 vertebral body metastasis.
GTV is shown in cyan. PTV is shown in light green. The spinal cord is shown
in red. The esophagus is shown in yellow. The skin is shown in pink. The
isodose curves are: red, 110% (19.8 Gy); white, 100% (18 Gy); blue, 80%
(14.4 Gy); cyan, 50% (9 Gy); and green, 25% (4.5 Gy).
FIGURE 2 | Actuarial prostate cancer-specific survival (CSS) in all
patients using the Kaplan–Meier method.
post-SBRT measurement. In 12 patients (71%), the serum PSA
had either yet to nadir or was undetectable at a median follow-up
of 5.2 months (range, 2.2–23.4 months). In patients with HRPC,
the PSA had either yet to nadir or was undetectable in 6 (55%)
of the 11 patients at a median follow-up of 4.8 months (range,
2.2–6.0 months). The median initial post-SBRT PSA of 0.58 ng/dl
(range,<0.1–140 ng/dl), was signiﬁcantly lower than the median
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Table 2 |Treatment outcomes for each patient.
PatientGS HRPC Site treated SBRT dose
(Gy)/fractions
Post-SBRT
HT
F/U time
(month)
Initial PSA
(ng/dl)
First post-SBRT
PSA (ng/dl)
PSA at last
F/U (ng/dl)
Acute
toxicity
Grade
1 3 + 3 Y L2 24/1 N 4.9 36.4 140 140 – –
L4 20/1
2 4 + 5 Y Rt 1st rib 18/1 N 5.3 17.9 14.2 1.7 – –
Lt scapula 18/1
L3–L5 18/1
3 4 + 4 N Rt sacrum 24/1 Y 2.2 2.7 <0.1 <0.1 – –
4 3 + 4 Y Lt ischium 24/3 Y 24.5 1.9 <0.1 69.4 – –
5 4 + 3 Y L4 24/1 Y 4.3 0.69 0.53 0.17 – –
6 3 + 4 Y RP LN 50/5 Y 4.4 1.1 <0.1 0.18 – –
7 3 + 4 Y Liver 60/3 Y 18.7 11.9 13.3 83 LFT elevation 1
8 4 + 5 Y S1 18/1 Y 2.5 1.5 1.1 0.12 – –
9 4 + 3 N Rt sacrum 24/1 Y 4.9 5.2 1.1 <0.1 – –
10 4 + 4 Y Lt pelvis 24/1 Y 6.0 0.13 <0.1 <0.1 – –
11 3 + 4 N Lt 8th rib 18/1 Y 21.6 0.38 <0.1 <0.1 Dyspnea 2
12 4 + 4 N T3 18/1 Y 23.4 2.1 <0.1 <0.1 Back
pain/nausea
2/1
T10 18/1
13 4 + 5 N L4 24/1 Y 9.5 3.7 0.59 <0.1 – –
14 4 + 5 Y L3 18/1 Y 5.3 4.9 4.7 1.2 – –
15 3 + 4 Y L5 24/1 Y 12.0 4.6 1.5 4.4 – –
16 3 + 4 Y Lt acetabulum 24/1 Y 2.2 1.4 0.58 0.46 – –
17 3 + 4 N Rt pelvis 30/3 Y 5.0 0.13 <0.1 <0.1 – –
GS, Gleason score; HRPC, hormone-refractory prostate cancer; SBRT, stereotactic body radiation therapy; HT, hormone therapy; F/U, follow-up; PSA, prostate-speciﬁc
antigen; RP LN, retroperitoneal lymph nodes; LFT, liver function test.
FIGURE 3 | Actuarial freedom from distant progression (FFDP) in all
patients using the Kaplan–Meier method.Y -axis represents probability
of distant control.
pre-SBRTPSAof 2.1 ng/dl (range, 0.13–36.4 ng/dl; p= 0.03). Sim-
ilarly, the median PSA at the most recent follow-up (0.17 ng/dl;
range, <0.1–140) was signiﬁcantly lower than the pre-treatment
PSA (p = 02).
No patient developed acute grade ≥3 toxicity following treat-
ment. Reported toxicities included one case each of grade 2
dyspnea and back pain. The patient experiencing back pain also
experienced grade 1 nausea. The patient treated for liver metas-
tases experienced a transient increase in liver enzymes, alanine
aminotransferase (ALT) and aspartate aminotransferase (AST),
each grade 1. No late toxicity has been reported.
DISCUSSION
Stereotactic body radiation therapy resulted in excellent LC in our
cohort of oligometastatic PCa patients, the majority of whom
had HR disease. More importantly, a quantiﬁable post-SBRT PSA
response was observed in 15 of 17 patients, albeit in many patients
who received hormone therapy post SBRT. PSA reached an unde-
tectable level in nine patients, including three patients with HRPC.
Likewise, 6 of 11 HR patients had either yet to experience a PSA
nadir or had anundetectablePSAat themost recent follow-up. The
long-term impact of this is unknown, but points to the biologic
effectiveness of the SBRT in a HR setting.
Nearly two-thirds of patients with bone metastases will experi-
ence symptoms as a result of their bone disease (Coleman, 2001).
Skeletal-related events (SREs), including pathologic fractures or
Frontiers in Oncology | Radiation Oncology January 2013 | Volume 2 | Article 215 | 4
“fonc-02-00215” — 2013/1/21 — 15:24 — page 5 — #5
Ahmed et al. SBRT for prostate metastases
spinal cord compression, are common in patients with HRPC,
with 50% of patients with bone metastases experiencing ≥1 SRE
(Lage et al., 2008). SREs are associated with decreased quality of
life and increased health care expenditures (Lage et al., 2008). As
such, patients with known bone metastases are followed closely
for any signs or symptoms that could be indicative of progres-
sive bone involvement. Potential interventions to prevent SREs
include surgery, palliative EBRT, or other local therapies, such
as cryotherapy and radiofrequency ablation. SBRT has a possible
advantage in that it is both a non-invasive and highly tumoricidal
treatment technique. Single fraction SBRT, which was used in the
majority of the patients with bony lesions in the current study,
has also been shown to be highly effective for the palliation of
symptomatic bony lesions and the prevention of SREs (Yamada
et al., 2008). In the setting of oligometastatic cancer, SBRT offers
many advantages over conventional EBRT. With SBRT, patients
are offered a shorter treatment course improving quality of life
and time outside the hospital setting. Hypofractionated SBRT also
offers a more effective radiobiologic dose, the ability to treat in
the setting of reirradiation, and the ability to treat less normal
anatomy (Mahadevan et al., 2011).
Monitoring tumor response to treatment is vital in themanage-
ment of cancer patients. Unlike treatment in the deﬁnitive setting,
where physical examination and imaging studies are required to
determine treatment response, an improvement in the symp-
tom(s) being palliated is often the most useful surrogate for
treatment response in the palliative setting. Determining treat-
ment response for patients with bony metastases in this setting
can be difﬁcult, as persistent tumor is often indistinguishable from
post-treatment bone remodeling. For patients with bony metas-
tases, a number of imaging-based algorithms have been set forth to
evaluate tumor response to local therapy, including criteria from
the World Health Organization (WHO, 1979), the International
Union Against Cancer (UICC; Hayward et al., 1977), and MD
Anderson (Costelloe et al., 2010). Yet the validity and reproducibil-
ity of some of these algorithms has been questioned (Hamaoka
et al., 2010). For patients with metastatic PCa, serum PSA values,
and PSA doubling time are frequently employed as metrics for
the systemic burden of disease (Sandler et al., 2000; Smith et al.,
2005). The ﬁndings of the current study, in which we were able
to show sustainable changes in a quantiﬁable surrogate for tumor
response such as serum PSA, are unique as this assessment can be
made independently of imaging studies. One potential weakness
of the study is that 15 of the 17 patients (88%) went on to receive
additional hormone therapy after SBRT, including a majority of
the patients with HR disease. Nonetheless, PSA appears to offer a
minimally invasive and cost effective method of evaluating tumor
response to treatment compared to serial imaging of the lesion in
question.
With the advent of SBRT and other ablative local therapies,
a more aggressive treatment approach is more often utilized
for asymptomatic patients with oligometastatic disease (Okunieff
et al., 2006; Salama et al., 2008). Recently, Muacevic et al. (2011)
reported on the use of SBRT for bony metastatic PCa lesions. The
study included 40 patientswith 64 bonemetastases, all treatedwith
single-fraction SBRT. Patientswere considered for SBRT regardless
of their hormone therapy responsiveness. With a mean follow-up
of 14 months, the authors report excellent response rates, with
6, 12, and 24-month estimates of LC of 95.5%. They also report
signiﬁcant decreases in PSA following treatment, with an initial
median PSA of 5.4 ng/dl (CI: 1.4–8.2) that dropped to 2.7 ng/dl
(CI: 0.14–10) 3 months following SBRT. In the current study, we
report similar ﬁndings, with excellent LC and PSA response, albeit
in a smaller cohort of patients. One unique ﬁnding of the current
study is that over 50% of the patients with HR disease had either
undetectable serum PSA levels or had PSA levels that were still
declining.
Toxicity of treatment is an important consideration when treat-
ing patients with metastatic disease. SBRT used in this trial was
well tolerated with only two reports of grade 2 toxicity in 21
treated lesions (9.5%) and no cases of grade ≥3 toxicity noted.
This compares favorablywithmore traditional palliative regimens.
For example, RTOG 9714 compared 8 Gy in 1 fraction to 30 Gy
in 10 fractions (Hartsell et al., 2005). The grade 2+ toxicity rate
was 17% for 30 Gy and 10% for 8 Gy. While this study is too small
to accurately compare toxicity with large randomized studies, it
does suggest SBRT regimens are very tolerable and perhaps more
so than traditional palliative regimens.
Most other studies of SBRT for oligometastatic cancer, although
retrospective in nature, have shown SBRT to be a favorable
treatment modality due to a mild toxicity proﬁle, improved dis-
ease control, shorter treatment course, and minimal invasiveness
(Yamada et al., 2008; Sahgal et al., 2009; Stauder et al., 2011;Ahmed
et al., 2012; National Cancer Institute, 2006). While intriguing, the
results fromour study shouldbe validated in a in aprospective clin-
ical trial. Doing so will allow for better identiﬁcation of patients
withmetastatic PCamost likely to beneﬁt fromSBRTas opposed to
other treatment options such as chemotherapy, immunotherapy,
or less-aggressive localized palliative therapy such as conventional
EBRT. It should also be noted that the majority of patients in this
study received hormone therapy following SBRT, adding a con-
founding variable in our use of PSA as a measure of response to
radiotherapy. Nonetheless, this study is one of few reports to assess
SBRT for the treatment of PCa metastases that includes patients
with HR disease.
CONCLUSION
These preliminary results suggest SBRT is a safe and effective treat-
ment for PCametastases. A subset of patientswithHRdiseasewere
found to have reductions in serumPSA values, withmore than half
of all patients achieving an undetectable serum PSA value. This
study provides data suggesting SBRT results in excellent LC with a
corresponding PSA response and an acceptable toxicity proﬁle in
properly selected patients with metastatic PCa.
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